Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

about

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

Item

http://www.wikidata.org/entity/Q47141507

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@en

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@nl

type

Item

label

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@en

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@nl

prefLabel

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@en

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@nl

P1476

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

@en

P2093

Christian Langer

http://www.w3.org/2001/XMLSchema#string

Jan Krönke

http://www.w3.org/2001/XMLSchema#string

Stefan Knop

http://www.w3.org/2001/XMLSchema#string

P2860

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

P304

106163-106164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.18632/ONCOTARGET.22572

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29290933

http://www.w3.org/2001/XMLSchema#string

P932

5739718

http://www.w3.org/2001/XMLSchema#string